Downregulation of mucosal mast cell activation and immune response in diarrhoea‐irritable bowel syndrome by oral disodium cromoglycate: A pilot study

Abstract

Oral DSCG modulates mucosal immune activity and improves gut symptoms in IBS-D patients. Future placebo-controlled clinical trials are needed for confirmation of clinical benefit of DSCG for IBS-D.